Lawrence A. Kenyon President, CEO and CFO 7 Clarke Drive Cranbury, NJ 08512

 

 

June 24, 2019

Via Edgar

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Sonia Bednarowski

 

	RE:	Outlook Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-231922
		Acceleration Request Requested Date: June 26, 2019 Requested Time: 5:00 P.M. Eastern Time

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on June 26, 2019, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.

 

Once the Registration Statement has been declared effective, please orally confirm that event with Marianne Sarrazin of Cooley LLP at (415) 693-2157 or Pia Kaur of Cooley LLP, at (415) 693-2135.

  

	Very truly yours,
	Outlook Therapeutics, Inc.
	By:	/s/ Lawrence A. Kenyon
		Lawrence A. Kenyon
		President, Chief Executive Officer and Chief Financial Officer

 

cc:	Yvan-Claude Pierre, Cooley LLP
	Marianne Sarrazin, Cooley LLP
	Pia Kaur, Cooley LLP